News Related to Difamilast

Related coverage linked through entity extraction aliases.

Aurobindo Pharma Subsidiaries Secure FDA, Health Canada, and EU Biosimilar Approvals and Partnerships

May 01, 2026

Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.

FDA Approves Difamilast Ointment for Atopic Dermatitis

Mar 09, 2026

The FDA has approved topical difamilast, a PDE4 inhibitor, for treating mild-to-moderate atopic dermatitis in adults and children aged 2 years or older, marking the third PDE4 inhibitor approval for this indication.